This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kokado, H. Articles by Mabuchi, H. Search for Related Content PubMed PubMed Citation Articles by Kokado, H. Articles by Mabuchi, H. Related Collections Clinical genetics

(Circulation. 2000;102:663.)
© 2000 American Heart Association, Inc.

Clinical Investigation and Reports

Clinical Features of Hypertrophic Cardiomyopathy Caused by a Lys183 Deletion Mutation in the Cardiac Troponin I Gene

Hiromasa Kokado, MD; Masami Shimizu, MD; Hiroyuki Yoshio, MD; Hidekazu Ino, MD; Kazuyasu Okeie, MD; Yorito Emoto, MD; Toru Matsuyama, MD; Masato Yamaguchi, MD; Toshihiko Yasuda, MD; Noboru Fujino, MD; Hideki Ito, MD; Hiroshi Mabuchi, MD

From The Second Department of Internal Medicine, School of Medicine, Kanazawa University, Kanazawa, Japan.

Correspondence to Hiromasa Kokado, MD, The Second Department of Internal Medicine, School of Medicine, Kanazawa University, Takara-machi 13-1, Kanazawa 920-8640, Japan. E-mail fcc13{at}lilac.ocn.ne.jp

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Background—Mutations that cause hypertrophic cardiomyopathy (HCM) have been identified in 9 genes that code proteins in the sarcomere. Previous reports have demonstrated that cardiac troponin I (cTnI) gene mutations may account for familial HCM; however, the clinical characteristics and prognosis of patients with HCM caused by cTnI gene mutations are not known.

Methods and Results—We analyzed cTnI gene mutations in 130 unrelated probands with HCM and their families to clarify the genotype-phenotype correlations. We identified 25 individuals in 7 families with a Lys183 deletion (Lys183 del) mutation in exon 7 of the cTnI gene. The disease penetrance in subjects aged >20 years was 88% by echocardiography and 96% by ECG. Sudden death occurred in 7 individuals of 4 families at any age. Overall, 7 (43.8%) of 16 individuals aged >40 years had left ventricular systolic dysfunction, and 3 (18.8%) displayed dilated cardiomyopathy-like features. Of affected individuals, 4 of 5 individuals aged >40 years followed by echocardiography showed septal thinning and decreased fractional shortening during >5 years of follow-up.

Conclusions—The Lys183 del mutation in the cTnI gene in patients with HCM is associated with variable clinical features and outcomes. HCM caused by the Lys183 del mutation has a significant disease penetrance. This mutation is associated with sudden death at any age and dilated cardiomyopathy-like features in those aged >40 years. However, it remains unclear whether screening of families with HCM for this mutation will be useful in patient management and counseling.

Key Words: hypertrophy • cardiomyopathy • genes • prognosis • proteins

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Hypertrophic cardiomyopathy (HCM) is a primary myocardial disease with varying morphological, functional, and clinical features.¹ Inheritance of HCM is often autosomal dominant. Recent advances in molecular genetics have made it possible to investigate the etiology of HCM at the DNA level. HCM can be caused by a mutation in any 1 of the following 9 genes that encode proteins in the sarcomere: ß-cardiac myosin heavy chain (chromosome 14), -tropomyosin (chromosome 15), cardiac troponin T (cTnT, chromosome 1), cardiac troponin I (cTnI, chromosome 19), cardiac myosin binding protein C (chromosome 11), cardiac myosin regulatory light chain (chromosome 12), cardiac myosin essential light chain genes (chromosome 3), -cardiac actin (chromosome 1), and titin (chromosome 2).^{2 3 4 5 6 7 8} Although several pathological mutations have been defined for HCM, the clinical consequences of these genetic defects and their contribution to the incidence of disease are not completely understood. Recently, 6 mutations (5 missense and 1 deletion in exons 7 and 8) in the cTnI gene were identified. Only 1 family with 2 individuals affected with a Lys183 deletion (Lys183 del) mutation has been reported.⁶ However, the clinical characteristics and prognosis of patients with cTnI gene mutations are not known. We analyzed this gene in individuals from families with HCM to further clarify the genotype-phenotype correlations caused by cTnI mutations.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Subjects
Study subjects were composed of 130 unrelated probands with familial and sporadic HCM; 73 cases had family histories (familial HCM), whereas apparent family history was not observed in the other 57 cases (sporadic HCM). All probands were identified at the Kanazawa University Hospital or its related hospitals (from primary to tertiary care centers). The diagnosis of HCM was based on the echocardiographic demonstration of a nondilated hypertrophied left ventricle in the absence of other cardiac or systemic causes for the left ventricular hypertrophy.⁹ These patients also met the definition and classification proposed by the 1995 World Health Organization/International Society and Federation of Cardiology Task Force.¹⁰ Family members whose probands had a Lys183 del mutation were studied genetically and clinically. Informed consent was obtained from all subjects or from the parents of minors participating in the study.

Detection of Mutation
DNA was isolated from peripheral white blood cells of all subjects by use of a DNA extractor 341 Nucleic Acid Purification System (GENEPURE, Applied Biosystems). In vitro amplification of genomic DNA was performed via polymerase chain reaction (PCR). Oligonucleotide primers were used to amplify exon 7 of the cTnI gene as described previously.⁶ Single-strand conformational polymorphism analysis of amplified DNA was then performed by use of a previously described method,¹¹ with a slight modification. For abnormal single-strand conformational polymorphism patterns, PCR products were subcloned into the pCR2.1 vector by using the TOPO TA cloning kit (Invitrogen). The nucleotide sequences of the cloned PCR products were determined on both strands by the dye terminator cycle sequencing method with use of an automated fluorescent sequencer (ABI PRISM 310 Genetic Analyzer, Applied Biosystems). Family members of the affected probands were evaluated similarly. Samples from 100 normal individuals were also analyzed.

Clinical Evaluations
Evaluation of the phenotype was completed before determination of the genotype. All probands and family members underwent 12-lead ECG and M-mode and 2D echocardiography. The distribution of left ventricular hypertrophy was assessed primarily in the parasternal long-axis view, although the parasternal short-axis and the apical 2- and 4-chamber views were also used to integrate the information obtained from the long-axis images. Disease penetrance was determined by the following criteria: (1) left ventricular end-diastolic maximal wall thickness 13 mm, (2) presence of major abnormalities on the ECG (ie, SV₁+RV_5/63.5 mV, Q wave 0.04 seconds or Q wave 1/4 the R wave amplitude and significant ST-T changes), or (3) a combination of criteria 1 and 2. Family members were evaluated similarly.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Genetic Results
Overall, 130 probands with familial and sporadic HCM (96 men and 34 women) were screened for mutations in the cTnI gene. A Lys183 del mutation was identified in 7 probands (Figure 1). Relatives of these 7 probands were studied further, totaling 47 members of the various families (Figures 2A and 2B). Of these 47 individuals, 25 (8 men and 17 women, mean age 47.8±19.1 years) had a Lys183 del mutation in the cTnI gene. This mutation has been identified previously as the HCM gene.⁶ This mutation was not detected in the 100 unrelated normal individuals (data not shown).

View larger version (59K): [in this window] [in a new window]   Figure 1. Partial sequence of exon 7 in cTnI gene. PCR product of exon 7 from patient was cloned and sequenced. Codon 183 of normal allele is AAG, and that of mutant allele is deleted, showing that patient is heterozygous in terms of deletion at codon 183.

View larger version (27K): [in this window] [in a new window]   Figure 2. A, Pedigree of family 001 with HCM caused by Lys183 del mutation in cTnI gene. Genotypic and phenotypic status of subjects is indicated in key. Ages of patients who died suddenly are shown in parentheses. B, Pedigrees of families 070, 006, 075, 088, 104, and 020 with HCM caused by Lys183 del mutation in cTnI gene.

Clinical Features
Of the 7 proband families studied, 47 individuals underwent clinical evaluation. Table 1 shows the echocardiographic and ECG data of the 25 individuals affected genetically. Asymmetrical septal hypertrophy (interventricular septal wall thickness 13 mm, interventricular septal thickness/LV posterior wall thickness 1.3) was found in 13 subjects (52.0%). The mean maximal left ventricular wall thickness was 14.2±4.8 mm. Left ventricular systolic dysfunction (fractional shortening <25%) was observed in 7 of 16 individuals aged >40 years. Maximal left ventricular wall thickness was 13 mm in these 7 individuals (mean 10.6±2.1 mm). Left ventricular end-diastolic dimension was >50 mm in 6 of these 7 individuals. However, fractional shortening was >25% in all subjects aged <40 years. Echocardiographic abnormalities were noted in 21 of 25 affected subjects. On ECG, 20 individuals had sinus rhythm, 1 had junctional rhythm, 3 had chronic atrial fibrillation, and 1 had paroxysmal atrial fibrillation. Q waves were noted in 17 subjects (SV₁+RV₅3.5 mV in 12 subjects and significant ST-T changes in 22 subjects). One subject had deep inverted T waves (-1.0 mV) in the precordial leads. All individuals, except for V-6 of family 001 and III-2 of family 075, had echocardiographic and/or ECG abnormalities.

View this table: [in this window] [in a new window]   Table 1. Echocardiographic and ECG Findings in the Affected Individuals

View this table: [in this window] [in a new window]   Table 1A. Continued

Clinical Course and Sudden Death
We followed 6 individuals for >5 years (8.7±2.5 years, range 6 to 13 years). Table 2 and Figure 3 show the echocardiographic changes during >5 years of follow-up. Four members of family 001 developed left ventricular systolic dysfunction and thinning of the hypertrophied septum. One in particular, IV-6, progressed to dilated cardiomyopathy-like features (fractional shortening was <25%, and left ventricular end-diastolic dimension was 55 mm) in the fourth decade of life. In regard to treatment, ß-blockers had been used in 2 individuals, and calcium antagonists had been used in 4 of 6 individuals. Nevertheless, 4 of 5 individuals aged >40 years followed by echocardiography showed septal thinning and decreased fractional shortening during >5 years of follow-up. Overall, sudden death occurred in 7 participants (Figures 2A and 2B), and it occurred in any generation from the teens to the 70s (mean age 45.3±17.3 years). All individuals with left ventricular systolic dysfunction were aged >40 years (mean 58.9±9.3 years), and 3 (18.8%) of 16 individuals aged >40 years demonstrated dilated cardiomyopathy-like features (Table 1).

View this table: [in this window] [in a new window]   Table 2. Echocardiographic Changes During >5 Years of Follow-Up

View larger version (11K): [in this window] [in a new window]   Figure 3. Echocardiographic changes during >5 years of follow-up. Four of 5 affected individuals aged >40 years followed by echocardiography over 5 years revealed decreased fractional shortening (FS) with thinning of the hypertrophied septum. Three of these 4 individuals progressed to left ventricular systolic dysfunction (fractional shortening <25%).

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
Six different mutations in the cTnI gene have been reported to cause familial HCM.⁶ The clinical characteristics and prognosis of patients with the Lys183 del mutation in the cTnI gene are unclear because affected individuals are rare. Our genetic analyses identified 25 individuals with the Lys183 del mutation in the cTnI gene. We evaluated the echocardiographic and ECG findings and the clinical course in individuals with the Lys183 del mutation in the cTnI gene.

Penetrance and Clinical Features
Moolman et al¹² have reported that the cTnT mutation, Arg92Trp, is characterized by low disease penetrance (40% by echocardiography and 66% by ECG) in HCM. On the other hand, Anan et al¹³ reported a greater penetrance with the Phe110Ile mutation of cTnT (94% by ECG and 81% by echocardiography). No previous reports have focused on the penetrance of cTnI gene mutations. In the present study, we observed that the disease penetrance in subjects aged >20 years was 88% (21 of 24 individuals) by echocardiography and 96% (23 of 24 individuals) on the basis of ECG abnormalities. ECG seems to be more sensitive than echocardiography in detecting disease-causing mutations. The Lys183 del mutation in the cTnI gene was characterized by high disease penetrance. Because the Lys183 del mutation of cTnI demonstrated high disease penetrance and because this mutation was found at the evolutionarily conserved amino acid of troponin I,^{14 15 16 17 18 19} this region is believed to be of increased functional significance. Because the same mutation has been reported previously,⁶ it may also be a mutant " hot spot."

Hecht et al²⁰ described 7 families with genetically transmitted HCM evaluated with echocardiography, necropsy, or both. Family members with HCM, despite a common genetic substrate, may exhibit markedly diverse and distinct expression of the natural history of their disease, which can occur at any age. Few studies have addressed the cardiac morphology of genotyped individuals with HCM. Phe110Ile substitution in the cTnT gene has been reported to cause HCM with variable cardiac morphologies.¹³ Kimura et al⁶ recently reported that 3 (8.3%) of 36 individuals with apical hypertrophy had mutations in the cTnI gene, suggesting that apical hypertrophy is a form of HCM, a disease of the sarcomere. They also reported that a patient with the Lys183 del mutation was diagnosed with apical HCM, whereas his son with the same mutation developed typical HCM. We found that the ventricular morphology of individuals with HCM caused by the Lys183 del mutation in the cTnI gene varied considerably, inasmuch as only 1 individual with this mutation showed apical hypertrophy with asymmetrical septal hypertrophy. None of our subjects had apical hypertrophy alone. Our analysis demonstrates that the distribution of hypertrophy among affected individuals varies within and between families.

Clinical Course and Prognosis
HCM is a slowly progressive disorder that manifests remarkable evolution of clinical features during its long-term natural course.^{20 21} Certain mutations in the ß-myosin heavy chain appear to carry more serious prognostic implications than others; some may be associated with a largely benign clinical course and near-normal life expectancy (eg, Val606Met),^22–25 whereas others have been reported in a relatively small number of families, leading to decreased survival due to either sudden catastrophic events or heart failure (eg, Arg403Gln, Arg453Cys, and Arg719Trp).^{22 23 24 25 26} Mutations in the gene for myosin-binding protein C appear to be associated with a relatively favorable clinical course, and a substantial proportion of genetically affected adults exhibits no phenotypic evidence of disease on echocardiography.²⁷ Six mutations in the cTnT gene (Ile79Asn, Arg92Gln, Arg92Trp, Ala104Val, Glu160 del, and intron 15 G₁A) have been associated with an increased incidence of sudden death,^{12 28 29} whereas the Phe110Ile mutation in cTnT has a benign outcome.¹³ Regarding the mutations in the cTnI gene, there is no report. We found 25 individuals from 7 families with the Lys183 del mutation. Sudden death occurred in 7 individuals from 4 families and could occur at any age from the teens to the 70s. One young individual (III-3 of family 075) died suddenly during jogging, but sudden death occurred during mild activity in another 3 individuals: 2 (III-19 and IV-16 of family 001) died during walking at the home and in the hospital, respectively, and 1 died shortly after taking a bath. The exact activity at the time of death was unknown in the other 3 individuals. In young apparently healthy athletes with HCM, sudden death is often the first manifestation of the disease.^{30 31 32} On the other hand, because previous studies revealed that an abnormal blood pressure response during exercise was more common in young HCM patients and that an abnormal blood pressure response was associated with an increased risk of sudden cardiac death,^{33 34} it is recommended that young patients with HCM avoid intense training and competition in particular. Of 25 genetically affected individuals, 7 individuals with left ventricular systolic dysfunction were aged >40 years, with 3 individuals displaying dilated cardiomyopathy-like features. These data suggest that individuals with HCM caused by the Lys183 del mutation in the cTnI gene are likely to die suddenly at any age and that systolic dysfunction, evidenced by dilatation of the left ventricular cavities and thinning of left ventricular wall, is common after age 40. The Lys183 del mutation is associated with a comparatively malignant clinical course; we suggest that this mutation is the deletion of a positively charged amino acid, and this region is believed to be of increased functional significance. The cTnI isoform is expressed only in cardiac muscles³⁵ and contains several functional domains: (1) the NH₂-terminal extension, which contains 2 sites at serine residues 23 and 24, the phosphorylation of which alters calcium sensitivity and eliminates cooperative binding to actin, (2) the near NH₂-terminal domain, which binds to the COOH terminus of cardiac troponin C containing 2 sites at serine residues 42 and 44, the phosphorylation of which reduces the maximum ATPase rate, (3) the inhibitory region that binds both actin and cardiac troponin C to induce relaxation via inhibition of the actomyosin interaction, and (4) the COOH-terminal domain, which is important for calcium sensitivity of the myofilaments.^{36 37} Because Lys183 in cTnI is within the C-terminal domain, the Lys183 del mutation may cause an alteration of the calcium-dependent regulation of cardiac myofilament contraction. On the other hand, Lys183 lies immediately to the C-terminal side of the important region that binds actin-tropomyosin and enhances the inhibitory effect.³⁸ In addition, it has been reported that deletions of 23 [cTnI-(1-188)] and 60 [cTnI-(1-151)] residues from the C-terminus of cTnI cause reduced inhibition of actomyosin ATPase activity.³⁷ The loss of inhibitory function may weaken the interaction of cTnI with actin-tropomyosin and may influence muscle contraction and relaxation. The report of Huang et al³⁹ describing that the cTnI gene knockout mouse showed elevated resting tension, reduced calcium sensitivity during the development of active force, and shortened sarcomeres supports our speculations. They also reported that slow skeletal troponin I (ssTnI) initially compensated for the absence of cTnI, but beginning at approximately day 15 after birth, a steady loss of ssTnI occurred, giving rise to heart failure.³⁹ Because of a small reduction in the potency of inhibition of actomyosin ATPase caused by the Lys183 del mutation⁴⁰ and heterozygous patients, the impaired function of cTnI in patients with the Lys183 del mutation may be compensated for by ssTnI at a young age. However, a loss of ssTnI may occur with increasing age and may lead to heart failure in individuals aged >40 years. Further investigation of the phenotype in the Lys183 del mutation is necessary.

In regard to treatment, of 6 individuals followed for >5 years (8.7±2.5 years), ß-blockers had been used in 2 individuals, and calcium antagonists had been used in 4. Currently, ß-blockers and calcium antagonists have been used extensively in the treatment of HCM. But whether these drugs should be used prophylactically to delay disease progression and improve the prognosis has been a subject of debate for many years. In our patients, 4 of 5 aged >40 years that were followed by echocardiography showed septal thinning and decreased fractional shortening during >5 years of follow-up. The effectiveness of prophylactic treatment has not been tested prospectively because study populations are small.

Limitations of the Study
Because this mutation shows low prevalence, it is unclear whether early genetic diagnosis could lead to an intervention that would alter the outcomes. Large-scale analysis is required to clarify the phenotype-genotype correlations in the future.

Conclusion
A Lys183 del mutation was found in 7 of 130 Japanese families with HCM. HCM caused by the Lys183 del mutation of the cTnI gene shows a high disease penetrance. Approximately half of the individuals with this mutation aged >40 years may exhibit left ventricular systolic dysfunction, and some may develop a dilated cardiomyopathy. Sudden death may occur in individuals with this mutation at any age.

Received November 9, 1999; revision received February 16, 2000; accepted March 2, 2000.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Spirito P, Seidman CE, McKenna WJ, et al. The management of hypertrophic cardiomyopathy. N Engl J Med. 1997;336:775–785.[Free Full Text]

2. Geisterfer-Lowrance AAT, Kass S, Tanigawa G, et al. A molecular basis for familial hypertrophic cardiomyopathy: a ß cardiac myosin heavy chain gene missense mutation. Cell. 1990;62:999–1006.[Medline] [Order article via Infotrieve]

3. Thierfelder L, Watkins H, MacRae C, et al. -Tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell. 1994;77:701–712.[Medline] [Order article via Infotrieve]

4. Watkins H, Conner D, Thierfelder L, et al. Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy. Nat Genet. 1995;11:434–437.[Medline] [Order article via Infotrieve]

5. Poetter K, Jiang H, Hassanzadeh S, et al. Mutations in either the essential or regulatory light chain of myosin are associated with a rare myopathy in human heart and skeletal muscle. Nat Genet. 1996;13:63–69.[Medline] [Order article via Infotrieve]

6. Kimura A, Harada H, Park J-E, et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet. 1997;16:379–382.[Medline] [Order article via Infotrieve]

7. Mogensen J, Klausen IC, Pedersen AK, et al. -Cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J Clin Invest. 1999;103:R39–R43.

8. Satho M, Takahashi M, Sakamoto T, et al. Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene. Biochem Biophys Res Commun. 1999;262:411–417.[Medline] [Order article via Infotrieve]

9. Maron BJ, Epstein SE. Hypertrophic cardiomyopathy: a discussion of nomenclature. Am J Cardiol. 1979;43:1242–1244.[Medline] [Order article via Infotrieve]

10. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology task force on the definition and classification of cardiomyopathies. Circulation. 1996;93:841–842.[Free Full Text]

11. Orita M, Suzuki Y, Sekiya T, et al. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics. 1989;5:874–879.[Medline] [Order article via Infotrieve]

12. Moolman JC, Corfield VA, Posen B, et al. Sudden death due to troponin T mutations. J Am Coll Cardiol.. 1997;29:549–555.[Abstract]

13. Anan R, Shono H, Kisanuki A, et al. Patients with familial hypertrophic cardiomyopathy caused by a Phe110Ile missense mutation in the cardiac troponin T gene have variable cardiac morphologies and a favorable prognosis. Circulation.. 1998;98:391–397.[Abstract/Free Full Text]

14. Drysdale TA, Tonissen KF, Patterson KD, et al. Cardiac troponin I is a heart-specific marker in the Xenopus embryo: expression during abnormal heart morphogenesis. Dev Biol. 1994;165:432–441.[Medline] [Order article via Infotrieve]

15. Leszyk J, Dumaswala R, Potter JD, et al. Amino acid sequence of bovine cardiac troponin I. Biochemistry. 1988;27:2821–2827.[Medline] [Order article via Infotrieve]

16. Grand RJ, Wilkinson JM. The amino acid sequence of rabbit cardiac troponin I. Biochem. J. 1976;159:633–641.[Medline] [Order article via Infotrieve]

17. Murphy AM, Jones L II, Sims HF, et al. Molecular cloning of rat cardiac troponin I and analysis of troponin I isoform expression in developing rat heart. Biochemistry. 1991;30:707–712.[Medline] [Order article via Infotrieve]

18. Ausoni S, Campione M, Picard A, et al. Structure and regulation of the mouse cardiac troponin I gene. J Biol Chem. 1994;269:339–346.[Abstract/Free Full Text]

19. Hastings KE, Koppe RI, Marmor E, et al. Structure and developmental expression of troponin I isoforms. cDNA clone analysis of avian cardiac troponin I mRNA. J Biol Chem. 1991;266:19659–19665.[Abstract/Free Full Text]

20. Hecht GM, Klues HG, Roberts WC, et al. Coexistence of sudden death and end-stage heart failure in familial hypertrophic cardiomyopathy. J Am Coll Cardiol. 1993;22:489–497.[Abstract]

21. Maron BJ, Bonow RO, Cannon RO, et al. Hypertrophic cardiomyopathy: interrelations of clinical manifestation, pathophysiology, and therapy. N Engl J Med. 1987;316:780–789/844–852.[Medline] [Order article via Infotrieve]

22. Schwartz K, Carrier L, Guicheney P, et al. Molecular basis of familial cardiomyopathies. Circulation. 1995;91:532–540.[Free Full Text]

23. Marian AJ, Roberts R. Recent advances in the molecular genetics of hypertrophic cardiomyopathy. Circulation. 1995;91:1336–1347.[Abstract/Free Full Text]

24. Watkins H, Rosenzweig A, Hwang D-S, et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med. 1992;326:1108–1114.[Abstract]

25. Marian AJ, Mares A Jr, Kelly DP, et al. Sudden cardiac death in hypertrophic cardiomyopathy: variability in phenotypic expression of ß-myosin heavy chain mutations. Eur Heart J. 1995;16:368–376.[Abstract/Free Full Text]

26. Anan R, Greve G, Thierfelder L, et al. Prognostic implication of novel ß cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest. 1994;93:280–285.

27. Niimura H, Bachinski LL, Sangwatanaroj S, et al. Mutations in the genes for cardiac myosin binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med. 1998;338:1248–1257.[Abstract/Free Full Text]

28. Watkins H, McKenna WJ, Thierfelder L, et al. Mutations in the genes for cardiac troponin T and a-tropomyosin in hypertrophic cardiomyopathy. N Engl J Med. 1995;332:1058–1064.[Abstract/Free Full Text]

29. Nakajima-Taniguchi C, Matsui H, Fujio Y, et al. Novel missense mutation in cardiac troponin T gene found in Japanese patient with hypertrophic cardiomyopathy. J Mol Cell Cardiol. 1997;29:839–843.[Medline] [Order article via Infotrieve]

30. Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: a profile in 78 patients. Circulation. 1982;65:1388–1394.[Abstract/Free Full Text]

31. McKenna W, Deanfield J, Farugui A, et al. Prognosis in hypertrophic cardiomyopathy: role of age and clinical electrocardiographic and hemodynamic features. Am J Cardiol. 1981;47:532–538.[Medline] [Order article via Infotrieve]

32. Maron BJ, Epstein SE, Roberts WC. Cause of sudden death in competitive athletes. J Am Coll Cardiol. 1986;7:204–214.[Abstract]

33. Frenneaux MP, Counihan PJ, Caforio ALP, et al. Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation.. 1990;82:1995–2002.[Abstract/Free Full Text]

34. Sadoul N, Prasad K, Elliott PM, et al. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation. 1997;96:2987–2991.[Abstract/Free Full Text]

35. Hunkeler NM, Kullman J, Murphy AM. Troponin I isoform expression in human heart. Circ Res. 1991;69:1409–1414.[Abstract/Free Full Text]

36. Solaro RJ, Van Eyk J. Altered interactions among thin filament proteins modulate cardiac function. J Mol Cell Cardiol. 1996;28:217–230.[Medline] [Order article via Infotrieve]

37. Rarick HM, Tu X, Solaro RJ, et al. The C-terminus of cardiac troponin I is essential for full inhibitory and Ca²⁺-sensitivity of rat myofibrils. J Biol Chem. 1997;272:26887–26892.[Abstract/Free Full Text]

38. Redwood CS, Moolman-Smook JC, Watkins H. Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy. Cardiovasc Res. 1999;44:20–36.[Abstract/Free Full Text]

39. Huang X, Pi Y, Lee KJ, et al. Cardiac troponin I gene knockout: a mouse model of myocardial troponin I deficiency. Circ Res. 1999;84:1–8.[Abstract/Free Full Text]

40. Redwood CS, Elliott K, Watkins HC. Defective inhibitory properties of human cardiac troponin I mutants that cause familial hypertrophic cardiomyopathy (FHC). Circulation. 1998;98(suppl I):I-466. Abstract.

This article has been cited by other articles:

				K Sakata, H Ino, N Fujino, M Nagata, K Uchiyama, K Hayashi, T Konno, M Inoue, H Kato, Y Sakamoto, et al. Exercise-induced systolic dysfunction in patients with non-obstructive hypertrophic cardiomyopathy and mutations in the cardiac troponin genes Heart, October 1, 2008; 94(10): 1282 - 1287. [Abstract] [Full Text] [PDF]

				Y. Wen, J. R. Pinto, A. V. Gomes, Y. Xu, Y. Wang, Y. Wang, J. D. Potter, and W. G. L. Kerrick Functional Consequences of the Human Cardiac Troponin I Hypertrophic Cardiomyopathy Mutation R145G in Transgenic Mice J. Biol. Chem., July 18, 2008; 283(29): 20484 - 20494. [Abstract] [Full Text] [PDF]

				J. Du, J. Liu, H.-Z. Feng, M. M. Hossain, N. Gobara, C. Zhang, Y. Li, P.-Y. Jean-Charles, J.-P. Jin, and X.-P. Huang Impaired relaxation is the main manifestation in transgenic mice expressing a restrictive cardiomyopathy mutation, R193H, in cardiac TnI Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2604 - H2613. [Abstract] [Full Text] [PDF]

				B. Iorga, N. Blaudeck, J. Solzin, A. Neulen, I. Stehle, A. J. L. Davila, G. Pfitzer, and R. Stehle Lys184 deletion in troponin I impairs relaxation kinetics and induces hypercontractility in murine cardiac myofibrils Cardiovasc Res, March 1, 2008; 77(4): 676 - 686. [Abstract] [Full Text] [PDF]

				J. Liu, J. Du, C. Zhang, J. W. Walker, and X. Huang Progressive troponin I loss impairs cardiac relaxation and causes heart failure in mice Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H1273 - H1281. [Abstract] [Full Text] [PDF]

				T. Kubo, H. Kitaoka, M. Okawa, Y. Matsumura, N. Hitomi, N. Yamasaki, T. Furuno, J. Takata, M. Nishinaga, A. Kimura, et al. Lifelong Left Ventricular Remodeling of Hypertrophic Cardiomyopathy Caused by a Founder Frameshift Deletion Mutation in the Cardiac Myosin-Binding Protein C Gene Among Japanese J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1737 - 1743. [Abstract] [Full Text] [PDF]

				M. Arad, M. Penas-Lado, L. Monserrat, B. J. Maron, M. Sherrid, C. Y. Ho, S. Barr, A. Karim, T. M. Olson, M. Kamisago, et al. Gene Mutations in Apical Hypertrophic Cardiomyopathy Circulation, November 1, 2005; 112(18): 2805 - 2811. [Abstract] [Full Text] [PDF]

				E. Biagini, F. Coccolo, M. Ferlito, E. Perugini, G. Rocchi, L. Bacchi-Reggiani, C. Lofiego, G. Boriani, D. Prandstraller, F. M. Picchio, et al. Dilated-Hypokinetic Evolution of Hypertrophic Cardiomyopathy: Prevalence, Incidence, Risk Factors, and Prognostic Implications in Pediatric and Adult Patients J. Am. Coll. Cardiol., October 18, 2005; 46(8): 1543 - 1550. [Abstract] [Full Text] [PDF]

				M. F. Cesta, C. J. Baty, B. W. Keene, I. W. Smoak, and D. E. Malarkey Pathology of End-stage Remodeling in a Family of Cats with Hypertrophic Cardiomyopathy Vet. Pathol., July 1, 2005; 42(4): 458 - 467. [Abstract] [Full Text] [PDF]

				J. Mogensen, R. T. Murphy, T. Kubo, A. Bahl, J. C. Moon, I. C. Klausen, P. M. Elliott, and W. J. McKenna Frequency and clinical expression of cardiac troponin I mutations in 748 consecutive families with hypertrophic cardiomyopathy J. Am. Coll. Cardiol., December 21, 2004; 44(12): 2315 - 2325. [Abstract] [Full Text] [PDF]

				T. Konno, M. Shimizu, H. Ino, M. Yamaguchi, H. Terai, K. Uchiyama, K. Oe, T. Mabuchi, T. Kaneda, and H. Mabuchi Diagnostic value of abnormal Q waves for identification of preclinical carriers of hypertrophic cardiomyopathy based on a molecular genetic diagnosis Eur. Heart J., February 1, 2004; 25(3): 246 - 251. [Abstract] [Full Text] [PDF]

				H. Terai, M. Shimizu, H. Ino, M. Yamaguchi, K. Uchiyama, K. Oe, K. Nakajima, J. Taki, M. Kawano, and H. Mabuchi Changes in Cardiac Sympathetic Nerve Innervation and Activity in Pathophysiologic Transition from Typical to End-Stage Hypertrophic Cardiomyopathy J. Nucl. Med., October 1, 2003; 44(10): 1612 - 1617. [Abstract] [Full Text] [PDF]

				T. Konno, M. Shimizu, H. Ino, T. Matsuyama, M. Yamaguchi, H. Terai, K. Hayashi, T. Mabuchi, M. Kiyama, K. Sakata, et al. A novel missense mutation in the myosin binding protein-C gene is responsible for hypertrophic cardiomyopathy with left ventricular dysfunction and dilation in elderly patients J. Am. Coll. Cardiol., March 5, 2003; 41(5): 781 - 786. [Abstract] [Full Text] [PDF]

				M. Arad, J.G. Seidman, and C. E. Seidman Phenotypic diversity in hypertrophic cardiomyopathy Hum. Mol. Genet., October 1, 2002; 11(20): 2499 - 2506. [Abstract] [Full Text] [PDF]

				R. Lang, A. V. Gomes, J. Zhao, P. R. Housmans, T. Miller, and J. D. Potter Functional Analysis of a Troponin I (R145G) Mutation Associated with Familial Hypertrophic Cardiomyopathy J. Biol. Chem., March 29, 2002; 277(14): 11670 - 11678. [Abstract] [Full Text] [PDF]

				O. M. Hernandez, P. R. Housmans, and J. D. Potter Plasticity in Skeletal, Cardiac, and Smooth Muscle: Invited Review: Pathophysiology of cardiac muscle contraction and relaxation as a result of alterations in thin filament regulation J Appl Physiol, March 1, 2001; 90(3): 1125 - 1136. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kokado, H. Articles by Mabuchi, H. Search for Related Content PubMed PubMed Citation Articles by Kokado, H. Articles by Mabuchi, H. Related Collections Clinical genetics